Zevra Therapeutics, Inc.
NASDAQZevra Therapeutics heads into the post-earnings stretch with a clean beat under its belt and shorts sitting at a meaningful but steady 8.5% of the float. Q1 2026 results, reported after the close on May 6, came in well ahead of expectations. Adjusted EPS landed at $0.18, more than double the $0.08 consensus estimate. Revenue of $36.2 million beat the $32.0 million forecast — a…
Snapshot as of 7 May 2026
Zevra Therapeutics heads into the post-earnings stretch with a clean beat under its belt and shorts sitting at a meaningful but steady 8.5% of the float. Q1 2026 results, reported after the close on May 6, came in well…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ZVRA — free to start on ORTEX.
Sign up for free →Open ZVRA on ORTEX